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Objective: The Costs of Diabetes in Europe–Type 2 study
(CODE-2®, SmithKline Beecham plc) measures costs 
of managing patients with type 2 diabetes mellitus in
Germany. The aim of this analysis was to assess the uncer-
tainty of these estimates.
Design and Setting: The German study arm was based on
a sample of 809 patients with type 2 diabetes registered
in general practices. Information on socioeconomic data,
medical resource use, and clinical data was collected 
retrospectively for 1998.
Patients and Participants: Patients were grouped in ﬁve
strata based on their complication status, because of the
high impact of complications on costs. To obtain higher
credibility of resulting estimates, rare complication
groups were overrepresented. To be representative, results
were weighted using real prevalence data on complica-
tions from a prestudy.
Main Outcome Measures and Results: Within each
stratum, results were calculated as arithmetic mean
except for demographic data, where the median was
applied as input for weighted averages. Because the
degree of precision of calculated estimates was not acces-
sible analytically, 95% conﬁdence intervals (CIs) were
computed via bootstrapping of 10,000 independent boot-
strap samples for each of the calculated estimates. All
costs are given for the payers’ perspective in German
Deutsche Mark (DM). Costs per patient and year for
ambulatory care were DM 775 with 95% CI (721–835),
for hospitalizations DM 2771 (2242–3342), for drug
treatment DM 1496 (1399–1598), and for rehabilita-
tion DM 120 (70–177). The indirect cost was DM 372
(144–645). From the perspective of the sickness funds,
cost per patient and year was DM 5539 (5184–5894).
Mean HbA1c status was 7.51% (7.37–7.66) with the
majority of patients not achieving glycemic control below
6.5%.
Conclusion: Bootstrap CIs are remarkably narrow. Com-
bining a weighted stratiﬁcation with bootstrap estimation
is an appropriate method for analyzing the weighted
average of highly variable and skewed parameters such
as costs of diabetes.
Keywords: diabetes complications, diabetes epidemiol-
ogy, bootstrap methods, costs.
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ABSTRACT
Introduction
Epidemiologic studies in collaboration with the
World Health Organization [1,2] indicate an
increased prevalence of diabetes mellitus world-
wide. Jönsson [3] examined the economic impact of
diabetes, which accounts for 2% to 3% of the total
health-care budget in every country. Rubin et al. [4]
investigated the situation for the United States in
1992, whereas Jönsson [5] reviewed cost studies in
Sweden, France, and the United States stressing the
importance of further epidemiologic and clinical
data for economic evaluations.
The cost-of-illness study, Costs of Diabetes in
Europe–Type 2 (CODE-2®, SmithKline Beecham
plc, Greenford, UK), provides actual costs and
further characteristics of type 2 diabetes mellitus,
such as treatment and HbA1c levels. Data for the
German study arm, which are solely considered
here, were collected cross-sectionally and retro-
spectively for the year 1998. Bootstrap procedures
and their application for calculating conﬁdence
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intervals (CIs) were used to assess the accuracy of
performed estimations. Details of the bootstrapp-
ing procedure are described under “Statistical 
Analysis.”
The following analysis presents demographic
data such as age and body mass index and indicates
the accuracy of estimated costs, glycemic control as
measured by HbA1c, and treatment characteristics
by bootstrapping CIs. In this way, current clinical
practice with respect to glycemic control was bench-
marked with the recommendations from the 
European Diabetes Policy Group [6]. The relevance
of the bootstrap method in this context and the




The German arm of CODE-2 was based on a
sample of patients with type 2 diabetes [7]. A
prestudy was performed to generate a representa-
tive overview of the frequency of complications and
to establish a pool of patients for more detailed
examination in the main study. In the prestudy, 144
general practitioners and diabetes specialists all
over Germany provided data on the complication
status of 2701 randomly selected patients with type
2 diabetes. Patients were grouped into ﬁve mutually
exclusive strata, j = 1, . . . , 5, based on their com-
plication status. Group 1 included patients with no
complications. Strata 2 to 4 were constructed in
such a way that they represented the most frequent
combinations of complications observed: 2)
patients with cardiovascular complications only; 3)
patients with neuropathy only or in combination
with cardiovascular complications; and 4) patients
with cerebrovascular complications only or in 
combination with other complications. Stratum 5
included all remaining patients.
The main study and detailed documentation 
of treatment strategies, medical parameters, and
resource use data were conducted retrospectively
for the year 1998 by face-to-face interviews with the
physicians on the basis of patient ﬁles. Irrespective
of the prevalence of the ﬁve strata in the prestudy,
it was intended to randomly select an approxi-
mately equal number of patients from each stratum.
The purpose of this procedure was to gain a sufﬁ-
cient number of patients with each type of compli-
cation proﬁle to obtain a high credibility of
estimates even for rare combinations of complica-
tions. To be representative at the patient level in
Germany, the results from each stratum must be
weighted with the representative prevalence rates of
each stratum determined in the prestudy.
Cost
Because documentation in patient charts in
Germany is generally very detailed, all resource 
use with respect to direct and indirect cost can be
derived from the patients’ charts. A number of
sources, especially published charges, were used for
cost resource units, and total costs were evaluated
from the payers’ perspective. Also, working inca-
pacity had to be considered because sickness funds
in Germany pay for sick leave from the 43rd day of
incapacity to work. Further information about def-
initions of data and cost methods have been pub-
lished [7,8].
Statistical Analysis
The ﬁnal sample sizes of each stratum in the main
study were: n1 = 230 in group 1; n2 = 191 in group
2; n3 = 153 in group 3; n4 = 139 in group 4; and
n5 = 96 in group 5. For each of the strata, we cal-
culated arithmetic means of total costs per patient
and per year and the ranges (minimum, maximum)
to demonstrate the skewness of the original data.
To extrapolate the results of the main study to a
population level, results from the strata were
weighted according to real prevalence data on com-
plications estimated in the prestudy [8] yielding:
p1 = 1311/2701 as the representative proportion of
patients in group 1; p2 = 727/2701; p3 = 310/2701;
p4 = 266/2701; and p5 = 87/2701.
Estimates
Let mj be the arithmetic mean of the observed vari-
able of interest in the jth stratum, with j = 1, . . . ,
5. Other than for demographic data, results on a
patient level were calculated in accordance with
Thompson and Barber [9] as a weighted average,
M, from the arithmetic mean in each stratum:
(1)
The arithmetic mean is sensitive to extremely
high-cost values but is important for the payers’
viewpoint. The patients’ viewpoint was taken for
demographic patient data such as age and body
mass index. Therefore, weighted averages from the
median in each stratum were computed as a robust
measure of the mean obtained by calculating the
median rather than the arithmetic mean for mj in
Equation 1.
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Bootstrapping
An analytical formulation for a point estimate of
the weighted average M is given in Equation 1. The
respective 95% CI can be regarded as a measure of
uncertainty of this estimate. To compute CIs in a
usual way, the distribution of the estimate must be
known. In this setting, however, the degree of pre-
cision of the point estimate cannot be measured
using traditional statistical methods because the dis-
tribution of M is analytically not known. The
reason is that the ﬁve strata may not be indepen-
dent in a stochastic sense because of the deﬁnition
of the groups. The attribution of a patient to one of
the ﬁve strata depends on his or her complication
status, which determines the costs involved. Fur-
thermore, there is no information on a possible
dependence structure. Theoretical assumptions
involved in the application of central limit theorems
[10], which are essential for a direct statistical
approach, are not met. Moreover, the weights, pj,
are estimates from our prestudy and are therefore
considered as random as is the estimated mj.
For these reasons, nonparametric bootstrap 95%
CIs indicating the uncertainty of the respective esti-
mate of M were calculated. In this way we did not
need any proper statistical assumptions on the dis-
tribution of the data or the desired estimate. Fur-
thermore bootstrap can be used to extrapolate the
results on the whole population by multiplying with
an estimate of total numbers of diagnosed cases
ranging between 3.5 and 4 million in Germany [11,
12].
The statistical basis for any kind of bootstrap
procedures is described in a fundamental paper by
Efron [13], popularized by Diaconis and Efron [14],
and presented with applications in biology by
Manly [15], for example. The basic idea is to gen-
erate independent samples with replacement from
the empirical distribution of observed data. The
desired estimate, or weighted average, is calculated
for each of the replicate samples. The resulting Mi
for the ith sample yield a distribution for the 
estimate of M.
For our purpose, bootstrap estimates can be
obtained after a two-phase calculation: In phase 1,
the distribution of M is computed. Phase 2 calcu-
lates a point estimate and the respective 95% CI.
Calculation of the bootstrap point estimate for M
is optional, as can be obtained directly using Equa-
tion 1.
Phase 1
To approximate the empirical distribution of esti-
mate M using a bootstrap sample, we must calcu-
late the components Mi, i = 1, 2, . . . , for each
sample. Any of these Mi is the weighted average of
the i th replicated sample of empirical, observed
data. It is therefore obtained in the same way as M
in Equation 1, where mj are the means of nj sampled
values from the data in stratum j. Each sample was 
randomly selected and taken independently with
replacement from the empirical distribution of the
variable considered in group j. Note that the
samples do not generally coincide with the under-
lying empirical distribution, but the distinct values
in the sample form a subset of the distinct values of
the original data. Suitable sampling procedures are
described explicitly by Karian and Dudewicz [16].
Pretrials showed that bootstrap estimates were
stable after 10,000 replicate samples in our context.
Therefore, we set the bootstrap sample size to
10,000 and generated Mi, i = 1, 2, . . . , 10,000.
However, the sample size required for stable esti-
mations here cannot be generalized, because it may
vary from one data set to another.
Finally the procedure ends up with a bootstrap
sample Mi of size 10,000 yielding a distribution 
of the weighted average M of the parameter of in-
terest. The distribution can be displayed as a 
histogram. An example is given in Figure 1 for the
estimate of the average cost for medication per
patient and per year. In principle, any moments of
the distribution of M can be calculated. However,
we focus on the calculation of 95% CIs below.
Phase 2
The mean P(Mi) of the histogram—or equivalently
the arithmetic mean of the 10,000 bootstrapped
values Mi —is a further point estimate of M and in
this way an alternative to the analytical point esti-
mate given in Equation 1. For a sufﬁciently large
number of replicate samples, these values will coin-
cide. The lower and upper bound of the 95% CI of
P(Mi) can be calculated as 2.5% and 97.5% per-
centiles (P2.5 and P97.5) of the bootstrapped distrib-
ution of M, respectively, and therefore directly
derived from the histogram. This percentile method
[17] is applicable in our setting because the boot-
strapped distributions of our estimates can be
regarded as symmetric and not signiﬁcantly differ-
ent from the normal distribution, as in Figure 1.
Thus bias-corrected and accelerated CIs [18] reduce
to percentile intervals. More formally the following
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(2)
For all calculations and graphical displays, the
software package MATLAB, release 10 (The Math-
works, Inc., Natick, MA), with statistics toolbox
was used.
Results
The weighted median age of the participants was
66 years, ranging from 39 to 96 years. The median
body mass index of 28 (range, 17–59) indicates
obesity in most patients. The median time since
diagnosis was 6 years (range, 0–58). The number of
physician contacts was typically 21 per patient per
year or “per patient-year” (range, 1–280).
Total costs per patient-year for the ﬁve stratiﬁed
samples are given in Table 1. Patients with no 
complications incur lower costs on average than
patients with complications. In particular, patients
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mean total costs. Moreover, the range of cost values
in each of the groups indicates heavily right-skewed
data.
To assess the uncertainty of cost estimates, fre-
quencies of type of diabetes treatment and level of
glycemic control on a representative patient level
95% bootstrap CIs for weighted averages were
computed. The bootstrap procedure was stable
after 10,000 replicate samples as indicated in the
Phase I subsection. Bootstrap sensitivity analyses
according to Nuijten [19] can be incorporated in a
straightforward way.
Figure 1 exempliﬁes the distribution of M by dis-
playing histograms of the bootstrapped values, Mi,
of costs for medication per patient per year in
Deutsche Mark (DM), where 1 DM = 0.51 Euro (€).
Absolute frequencies are indicated with bars, while
the line represents the corresponding normal
density. Although the original cost data were
heavily right-skewed, as is common for cost values,
the histogram of the bootstrapped weighted aver-
ages shows a very good ﬁt to the normal distribu-
tion (two-sided p-value from Kolmogorov–Smirnov
test of ﬁt of .65).
 
Figure 1 Histogram with absolute frequencies of the bootstrapped values of costs for medication per patient per year and corresponding
normal density line.
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Analyzing total costs (direct and indirect) with
95% bootstrap CIs for the weighted average, we
obtain total costs per patient per year for type 2 
diabetes mellitus of 5539 DM with a precision 
of ± 355 DM. Of these costs, hospitalizations
accounted for the greatest proportion (2771 ± 550),
followed by costs for medication (1496 ± 100), and
outpatient treatment (775 ± 57). Costs for working
inability (372 ± 250) and rehabilitation (120 ± 53)
are comparatively low.
With respect to credibility of estimates, the most
important cost estimates are quite precise, whereas
working incapacity and rehabilitation are provided
with rather large CIs because the empirical distrib-
ution of the observed data is extremely bimodal.
Most of the patients (98%) had no costs for
working inability whereas the remaining cases sum
up to 17,276 DM on average. Weighting according
to Equation 1 yields a point estimate of 372 DM
per patient-year. This estimate is in accordance with
the ofﬁcial work incapacity table of the Statistisches
Bundesamt [20] and ﬁgures for the year 1997, when
considering costs of 200 DM per work day lost. In
summary, the extreme bimodality of the given
sample size of 809 is the reason for the larger CIs
for both working inability and rehabilitation. The
results are summarized in Table 2.
The same bootstrap method is applied to the
measure of blood glucose control, HbA1c, and to
the treatment strategies for diabetes.
More than 50% of the patients are treated with
oral antidiabetic drugs, followed by insulin (28%)
and special diet (19%). Only diabetic patients with
diet and exercise treatment—indicating the least
severe cases—meet the recommended 6.5% glucose
level of the European Diabetes Policy Group [6] on
average. The other two treatment groups lie signif-
icantly above the 6.5% and above the overall
average. Furthermore, cases with a minimum 7-year
history of diabetes have signiﬁcantly worse glucose
levels than patients with a shorter history. Both
groups also show glucose levels signiﬁcantly above
6.5%. In Table 3, results are presented with the
respective 95% bootstrap CIs for the calculated
weighted averages. Overall, the CIs are rather small
and the estimates have low uncertainty other than
for working inability and rehabilitation. External
sources, however, conﬁrm the validity of the point
estimate for working inability costs [20].
Conclusions
Bootstrapping is a general way of obtaining the dis-
tribution of estimates one is interested in. We used
this method to construct CIs where the distribution
of the estimate of interest was not available and
hence classical statistical approaches could not be
applied. The histogram of our bootstrap sample Mi,
i = 1, . . . , 10,000 in Figure 1 shows an example of
the before-bootstrap analytically unknown distrib-
Table 1 Total costs in Deutsche Mark (DM) of type 2 diabetes mellitus within each
of the ﬁve groups (payers’ perspective)
Total costs per patient and year (DM)* Arithmetic mean Range (min–max)
Group 1: no complications 3,430 154–34,290
Group 2: only cardiovascular complications 6,639 298–91,152
Group 3: neuropathy or neuropathy + 6,527 128– 45,078
cardiovascular complications
Group 4: cerebrovascular complications or 10,293 435–131,271
cerebrovascular + other complications
Group 5: all other complications 10,012 531–94,343
*1 DM = 0.51 Euro (€) = 0.5 US$; 1 € = 1.96 DM = 0.98 US$.
Table 2 Costs of patients with type 2 diabetes mellitus in Germany in Deutsche
Mark (DM) from the payers’ perspective
Costs (DM)* Weighted average Bootstrap 95% CI
Direct cost per patient and year
Costs for outpatient treatment 775 721–835
Costs for inpatient treatment 2,771 2,242–3,342
Costs for medication 1,496 1,399–1,598
Costs for rehabilitation 120 70–177
Indirect costs per patient and year
Costs for working inability 372 144–645
Total costs per patient and year 5,539 5,184–5,894
*1 DM = 0.51 Euro (€) = 0.5 US$; 1 € = 1.96 DM = 0.98 US$.
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ution of M. To compute CIs in a classical way
assuming the normal distribution as indicated in
Figure 1, the standard deviation of the estimate
must be known. In our case, the standard deviation
of M is unknown in advance, as pj and mj are
random. The nonparametric bootstrap method cir-
cumvents the problem of specifying a dependence
structure for the ﬁve strata and yields the distribu-
tion and therefore any moments, such as the stan-
dard deviation of M, in a distribution-free manner.
In this way bootstrap is valuable in any cost-of-
illness study with skewed data, but necessary in 
situations where the distribution of estimates of
interest is unknown.
One may argue that bootstrap estimates are the
ﬁnal outcome of a random process and, thus, that
the results are completely random. However, if the
number of replicate samples is appropriately large,
the procedure will yield stable estimates. That is,
everyone gets the same results according to a pre-
viously deﬁned, ﬁxed accuracy even though the
numbers are random. In this way, the approach is
generally repeatable and reproducible.
A further drawback is that bootstrapping does
not yield direct, but only iterative, access to the con-
ﬁdence limits. Therefore, one obtains the outcome
of something like a black box. However, the way
the bootstrap procedures described on page 399
work is a sequential approach for generating distri-
butions of the desired estimates. Moreover, in situ-
ations where analytical approaches are unavailable,
bootstrapping is the only choice.
Third, bootstrapping is considered to be compu-
tationally demanding. With increasing computer
power, however, this point becomes of minor
importance. The CPU time for our MATLAB boot-
strap procedures was no longer than 10 minutes on
a Pentium III, 450-MHz processor.
Bootstrap CIs calculated from the histograms are
rather small for the essential variables analyzed in
this study. This indicates high credibility of our esti-
mates and a sufﬁciently high number of patients
enrolled in the main study for our purposes. Thus,
the combination of a weighted stratiﬁcation by cost
factors followed by bootstrap estimation is an
appropriate method for analyzing the average of
extremely variable and skewed parameters such as
costs of diabetes. This conﬁrms our previous ﬁnd-
ings [21].
Large CIs, however, indicate either uncertainty in
the estimation process or a high variation of sample
size ratio in the underlying observed data (e.g., costs
for working inability or rehabilitation).
In the CODE-2 study, the costs for type 2 dia-
betes mellitus were found to be very high for sick-
ness funds and, therefore, also for society. Although
there was much discussion about the economic
impact of diabetes, no comprehensive source of
data on the cost of type 2 diabetes, its management,
and its complications existed in Germany before
CODE-2 [22]. Most of the data available are
limited, especially with respect to the cost of com-
plications [22]. Furthermore, all published results
conﬁrm the enormous burden of disease and the
need to prevent complications and optimize
resource allocation [23–26].
This research was partly supported by GlaxoSmithKline,
Inc., Munich, Germany.
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